Global Cardiac Troponin Market Report and Forecast 2024-2032

Global Cardiac Troponin Market Outlook

The global cardiac troponin market is expected to grow at a CAGR of about 8.00% in the forecast period of 2024-2032, driven by the rising cases of heart failure.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America to be a Significant Regional Market for Cardiac Troponin

North America is anticipated to dominate the global cardiac troponin industry in the forecast period. Heart failure is a critical healthcare issue in the United States. It is highly prevalent and has high mortality and morbidity rate. The cost of care for heart diseases is high in the United States. The prevalence of heart failure in the country is expected to increase with an increasingly ageing population, driving the market growth in the region.

The market is also growing due to high expenditure on research and development, major players and their product availability, and the well-established healthcare infrastructure in the region. The increase aids the demand for cardiac biomarkers for cardiovascular disease diagnosis, a rise in the incidence of the acute coronary syndrome (ACS), advancements in the treatment, and growth in demand for point-of-care cardiac testing kits. The key market players' high specificity and sensitivity of these markers to detect cardiac disorders also contribute to the market growth.

Market Segmentations

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Troponin, a key regulatory protein of striated muscle's thin filament (actin), comprises three subunits: C, T, and I. Cardiovascular troponins are biomarkers or diagnostic markers used to detect myocardial infarction. Cardiac troponin is found in both skeletal and cardiac muscles, and a rise in cardiac troponin levels in the blood indicates the onset of myocardial infarction.

By type, the market includes:

• Troponin T
• Troponin I

Based on the site of testing, the market is divided into:

• Laboratory Testing
• Point-of-care Testing

The major applications of the market are:

• Acute Coronary Syndrome
• Myocardial Infarction
• Congestive Heart Failure
• Others

The end-uses of the market include:

• Hospitals
• Diagnostic Centres
• Homecare Settings
• Others

The several distribution channels of the market are:

• Manufacturer/ Distributor/ Service Provider
• Aftermarket

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The regional markets for the cardiac troponin industry can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Rising Demand for Cardiac Biomarkers to Diagnose Cardiovascular Diseases Augmenting the Market Growth

The global cardiac troponin industry is driven by the rising demand for cardiac biomarkers to diagnose cardiovascular diseases, the increasing prevalence of acute coronary syndrome, and the reduction in the burden of healthcare costs due to faster and acute diagnosis. Patients suffering from acute critical heart conditions require immediate results and quick diagnosis to avoid any causalities. Hence, physicians and doctors demand advanced use of cardiac troponins, pushing researchers and major companies to make investments. Major companies are focusing on the research and development of cardiac troponin tests and are aiming for the approval of new products to retain and enhance market competitiveness. For instance, in June 2018, Beckman Coulter Diagnostics received Health Canada clearance for its new high sensitivity troponin (hsTnI) assay, Access hsTnI, that aids in diagnosing myocardial infarction for patients presenting with chest pain or other ischemic symptoms.

Besides this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. An increase in the geriatric population and a rise in the number of patients suffering from heart attacks and chest pain due to lifestyle changes are expected to drive the market in the coming years.

Key Players in the Global Cardiac Troponin Market

The report gives a detailed analysis of the following key players in the global cardiac troponin industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Siemens Healthcare GmbH
• Eurolyser Diagnostica GmbH
• Beckman Coulter, Inc.
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report